XML 35 R24.htm IDEA: XBRL DOCUMENT v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On November 2, 2026, Rockwell Medical, Inc. entered into an Equity and Asset Purchase Agreement (the “Purchase Agreement”) with Vantive Limited (“Vantive”) pursuant to which the Company agreed to acquire Vantive's hemodialysis concentrates, hemodialysis machines, water treatment systems, and related consumables and technical services business, including Vantive's manufacturing campus located in Medolla, Italy. The acquisition is expected to significantly expand the Company's product portfolio, manufacturing capabilities and geographic reach. The transaction includes the acquisition of Gambro Dasco S.p.A. and Vantive Korea Incorporated and specified business assets and liabilities in other jurisdictions, subject to specified exclusions and possible deferred local transfers.

The aggregate base purchase price is $125.0 million, subject to customary working capital and other purchase price adjustments. The transaction is expected to be financed through two seller-provided term loans totaling $100.0 million and a $25.0 million convertible note to be issued to an affiliate of Vantive. In addition, the Purchase Agreement provides for contingent consideration of up to $45.0 million payable upon the achievement of specified revenue and EBITDA milestones. The Company may replace all or a portion of the seller term loans with qualifying third-party debt financing. The seller financing will become effective at closing; it does not provide cash for the Company’s pre-closing operations or transaction expenses. The contingent consideration comprises up to $25.0 million of EBITDA-based payments over eight full fiscal years after closing and two potential $10.0 million revenue-based payments, generally over five full fiscal years after closing, with a possible sixth-year extension for the second revenue milestone. Revenue earnout payments are subject to an annual payment limitation and may roll forward; specified unpaid amounts bear interest in addition to the $45.0 million maximum.

The unsecured convertible note will mature six years after closing, be subordinated in right of payment to specified senior debt and bear interest at 3.0% per annum payable in kind and will be convertible into shares of common stock at an initial conversion price of $14.94 per share, with the conversion price increasing on the same basis as ordinary PIK interest so that such interest does not increase the shares issuable in respect of the original principal. Subject to the note’s terms and applicable Nasdaq rules, issuances, together with other issuances required to be aggregated, may not exceed 19.99% of either the shares of common stock or voting power outstanding immediately before execution of the Purchase Agreement unless stockholder approval is obtained. The term loans will be secured by a lien on substantially all of the assets of the Company and its domestic subsidiaries and will mature on the sixth anniversary of the closing. The two initially $50.0 million tranches will bear interest at Term SOFR plus initial margins of 5.50% and 7.00%, respectively, increasing by 0.75 percentage points annually. Interest is payable monthly, although the Company may elect, subject to specified conditions, to capitalize interest on the first tranche at an additional 0.50% annual rate. The loans are subject to mandatory prepayments, restrictive covenants and customary events of default. Incurrence of the seller financing requires the consent of DaVita under the Securities Purchase Agreement described in Note 11, and at the closing the Company will repay in full and terminate the Loan Agreement described in Note 15.

The transaction is subject to customary closing conditions, including regulatory approvals and delivery of specified audited financial statements, completion of specified separation activities, execution of definitive transition services and manufacturing and supply agreements, and other conditions set forth in the Purchase Agreement, and is expected to close in mid-2027. The Purchase Agreement provides for an outside date of November 1, 2027, subject to extension in specified circumstances as provided therein. The Company is evaluating the accounting effects of the transaction and the financial impact of the acquisition cannot yet be reasonably estimated. The Company expects to incur additional transaction, financing and integration-related costs associated with the proposed acquisition.